Curcumin (CUR) is the prime curcuminoid in the Indian dietary spice turmeric, Curcuma longa, a plant of the Zingiberaceae family. CUR has promising and diverse therapeutic benefits, such as antioxidant, anti-inflammatory, antitumor, anti-hyperglycemic, antimalarial, antibacterial, and antiviral activity, including anti-Alzheimer's disease. However, CUR is yet to reach the status of a therapeutic drug candidate mainly because a standard solid dosage of curcumin suffers from poor oral bioavailability (0.05 μg mL−1, less than 1%). The reasons behind its low bioavailability include poor solubility (<8 μg mL−1 in water), low permeability and absorption, and rapid metabolism (short elimination half-life of <2 h). A successful CUR therapy requires an appropriate formulation system that will enhance the bioavailability and offer greater therapeutic efficacy. This review covers a comprehensive description of the CUR pharmaceutical solids, such as polymorphs, cocrystals, eutectics, and coamorphous solid-state forms with aim to determine ways to improve its physicochemical properties, including dissolution rate, solubility, physicochemical stability, mechanical strength, compressibility for tablet formation, and oral bioavailability. The cumulative publications in the past decade have forecast a bright future for development of an oral drug formulation of curcumin.

Authors: Kuthuru Suresh^a* and Ashwini Nangia^ab*

^aSchool of Chemistry, University of Hyderabad, Hyderabad 500 046, India

^bCouncil of Scientific and Industrial Research National Chemical Laboratory, Pune, 411 008, India

 *Correspondence e-mail: kuturusuresh@gmail.com,  ashwini.nangia@gmail.com

 Publication date : May 14^th, 2018